T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

• Main Authors: Ane Ogbe, Barbara Kronsteiner, Donal T. Skelly, Matthew Pace, Anthony Brown, Emily Adland, Kareena Adair, Hossain Delowar Akhter, Mohammad Ali, Serat-E Ali, Adrienn Angyal, M. Azim Ansari, Carolina V. Arancibia-Cárcamo, Helen Brown, Senthil Chinnakannan, Christopher Conlon, Catherine de Lara, Thushan de Silva, Christina Dold, Tao Dong, Timothy Donnison, David Eyre, Amy Flaxman, Helen Fletcher, Joshua Gardner, James T. Grist, Carl-Philipp Hackstein, Kanoot Jaruthamsophon, Katie Jeffery, Teresa Lambe, Lian Lee, Wenqin Li, Nicholas Lim, Philippa C. Matthews, Alexander J. Mentzer, Shona C. Moore, Dean J. Naisbitt, Monday Ogese, Graham Ogg, Peter Openshaw, Munir Pirmohamed, Andrew J. Pollard, Narayan Ramamurthy, Patpong Rongkard, Sarah Rowland-Jones, Oliver Sampson, Gavin Screaton, Alessandro Sette, Lizzie Stafford, Craig Thompson, Paul J. Thomson, Ryan Thwaites, Vinicius Vieira, Daniela Weiskopf, Panagiota Zacharopoulou, Oxford Immunology Network Covid-19 Response T Cell Consortium, Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team, Lance Turtle, Paul Klenerman, Philip Goulder, John Frater, Eleanor Barnes, Susanna Dunachie
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-04-01
• Series: Nature Communications
• Online Access: https://doi.org/10.1038/s41467-021-21856-3
• ISSN: 2041-1723

Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major effect on this discriminatory ability.